The companies will jointly develop a combination of the angiopoietin2 antibody nesvacumab and the anti-VEGF aflibercept for the treatment of wet AMD and diabetic macular edema.
Powered by Suchmaschinenoptimierung
AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Regeneron, Bayer to develop AMD combination therapy
- Details